 This is a Phase 1, single dose, open-label, sequential group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. This study will enroll approximately 6 subjects with mild hepatic impairment Child-Pugh A, approximately 6 subjects with moderate hepatic impairment Child-Pugh B, approximately 6 subjects with severe hepatic impairment Child-Pugh C, and approximately 18 matched non-hepatically impaired subjects. Non-hepatically impaired subjects in the control group will be matched to subjects with hepatic impairment based on age - 10 years and body weight - 20. Study Duration is approximately 15 months. Primary objective: To evaluate the pharmacokinetics of a single oral dose of PA-824 in subjects with mild, moderate, and severe hepatic impairment as assessed by Child-Pugh score, relative to matched non-hepatically impaired subjects. Secondary objective: To evaluate the safety of a single oral dose of PA-824 in subjects with mild, moderate, and severe hepatic impairment as assessed by Child-Pugh score, relative to matched non-hepatically impaired subjects. 